

Cover Story
Guest Editorial
By John H. Stewart and Robert A. Winn
Advances in the field of tumor immunotherapy have given great hope for those treating cancer. We are in an era of unprecedented achievements, as evidenced by impressive clinical responses in patients treated with adoptive cell therapy and immune checkpoint inhibitors.
By Claire Dietz and Matthew Bin Han Ong
In Brief
Clinical Roundup


Drugs & Targets


NCI Trials


NCI Trials for May
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
Trending Stories
- Backlog of work grows at NIH as staff members are being hounded to quit
- In the Headlines: What are Jay Bhattacharya’s plans for NIH?
- Rathmell: My mentor recognized a cliff I was going to fall off before I did.
“He was there to stand with me while I fell, and then made me look up and see that I needed to lean into the experience.” - The Directors: Ray DuBois and Roy Jensen on how COE guides cancer care in rural America
“We’re just going to have to ride through this and not give up.” - In support of three coordinated CCSG components reducing our national burden of cancer
- In the Headlines: Could “flooding the zone” drown NIH and cancer centers?